HEALTHCARE RESOURCE USE AND COSTS OF CARE IN HR+/HER2-METASTATIC BREAST CANCER: A RETROSPECTIVE US CLAIMS DATA STUDY

被引：0
|
作者：
Collin, S. [1 ]
Tse, J. [2 ]
Shaikh, N. F. [3 ]
Near, A. [2 ]
Hamilton, E. [4 ]
Brufsky, A. [5 ]
Gradishar, W. [6 ]
Mehta, S. [7 ]
Long, G. H. [1 ]
Toms, N. [1 ]
机构：
[1] AstraZeneca Pharmaceut Ltd, Cambridge, England
[2] IQVIA, Durham, NC USA
[3] IQVIA, Morgantown, WV USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[6] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[7] Daiichi Sankyo, Basking Ridge, NJ USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE417
引用
收藏
页码：S134 / S134
页数：1
相关论文
共 50 条
  • [21] Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2-metastatic breast cancer
    Li, Nanxin
    Du, Ella X.
    Chu, Lihao
    Peeples, Miranda
    Xie, Jipan
    Barghout, Victoria
    Tang, Derek H.
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (12) : 1167 - 1178
  • [22] REAL-WORLD ANALYSIS OF MEDICAL COSTS AND HEALTHCARE RESOURCE UTILIZATION IN ELDERLY WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER RECEIVING EVEROLIMUS-BASED THERAPY OR CHEMOTHERAPY
    Hao, Y.
    Li, N.
    Fang, A.
    Koo, V
    Peeples, M.
    Kageleiry, A.
    VALUE IN HEALTH, 2016, 19 (03) : A145 - A145
  • [23] Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2-Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy
    Hao, Yanni
    Li, Nanxin
    Fang, Anna P.
    Koo, Valerie
    Peeples, Miranda
    Kageleiry, Andrew
    Wu, Eric Q.
    Guerin, Annie
    ADVANCES IN THERAPY, 2016, 33 (06) : 983 - 997
  • [24] Breast cancer specific survival (BCSS) in HR+/HER2-metastatic breast cancer (mBC) from 2010 to 2019
    Brufsky, A. M.
    Kwan, M.
    Sandin, R.
    Karanth, S.
    Cha-Silva, A.
    Makari, D.
    Stergiopoulos, S.
    Goyal, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S351 - S352
  • [25] Economic impact of longer treatment duration in first-line for HR+/HER2-metastatic breast cancer: A retrospective analysis
    Abbass, Ibrahim M.
    Ng, Carmen
    Dillon, Allison
    Cheng, Anna
    Du Toit, Yolande
    Basho, Reva K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] Observational study of HR+/HER2-metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS)
    Blanch, Salvador
    Gil-Gil, Juan Miguel
    Arumi, Miriam
    Aguirre, Elena
    Segui, Miguel Angel
    Atienza, Manuel
    Diaz-Cerezo, Silvia
    Molero, Alberto
    Cervera, Jose Manuel
    Gavila, Joaquin
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (10): : 2950 - 2959
  • [27] VIRTUAL COMMUNITY ENGAGEMENT AMONG WOMEN RECEIVING PALBOCICLIB FOR HR+/HER2-METASTATIC BREAST CANCER: DATA FROM THE MADELINE STUDY
    Richardson, D.
    Zhan, L.
    Reynolds, M.
    Odom, D.
    McRoy, L.
    Mitra, D.
    Zelnak, A.
    Jones, C.
    VALUE IN HEALTH, 2019, 22 : S527 - S527
  • [28] Identifying drivers of first-line HR+/HER2-metastatic breast cancer treatment choices
    Brufsky, Adam
    Maculaitis, Martine C.
    Kopenhafer, Lewis
    Olsen, Patrick
    Kurosky, Samantha K.
    Arruda, Lillian Shahied
    Heck, Wendy
    Cha-Silva, Ashley S.
    FUTURE ONCOLOGY, 2024,
  • [29] Results of a retrospective study on the efficacy and safety of alpelisib in patients with HR+/HER2-metastatic breast cancer in real-world clinical practice
    Sultanbaev, Alexander Valerievich
    Kolyadina, Irina Vladimirovna
    Menshikov, Konstantin
    Musin, Shamil
    Sultanbaeva, Nadezda
    Lipatov, Danila
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Identifying Drivers of First-Line HR+/HER2-Metastatic Breast Cancer Treatment Choices
    Brufsky, Adam M.
    Maculaitis, Martine C.
    Kopenhafer, Lewis
    Olsen, Patrick
    Cha, Ashley S.
    Arruda, Lillian Shahied
    Heck, Wendy
    Kurosky, Samantha K.
    CANCER RESEARCH, 2023, 83 (05)
12345